This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales in Q3 and raises guidance for the full year
Pfizer (PFE) Beats on Q3 Earnings, Meets Sales, Narrows View
by Zacks Equity Research
Pfizer's (PFE) third-quarter earnings beat estimates while sales match the same. The company narrows its full-year sales and profit targets
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
Pfizer (PFE) Q3 Earnings Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 2.63% and -0.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Stocks Attempt Rally, IBM Buys Red Hat, & Q3 Earnings Season Stays Hot
by Ryan McQueeney
Ryan McQueeney checks in with the market's major indexes as Wall Street hopes for a rally from the recent extended selloff. He also recaps a few headlines, including IBM's acquisition of Red Hat and the morning's top earnings news.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.
BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q3 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs
by Zacks Equity Research
Pfizer (PFE) and Lilly present detailed data from a phase III study on pain candidate, tanezumab. The former forms a new company for CNS treatment in alliance with Bain Capital.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
Pfizer (PFE) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.37, marking a -0.29% move from the previous day.
QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.
Top-Ranked Healthcare ETFs for Long-Term Investors
by Neena Mishra
Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
The Zacks Analyst Blog Highlights: Pfizer, Caterpillar, Charter Communications, Sherwin-Williams and Pioneer Natural
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Caterpillar, Charter Communications, Sherwin-Williams and Pioneer Natural
Sarepta Announces Agreement With Lysogene for Gene Therapy
by Zacks Equity Research
Sarepta Therapeutics (SRPT) signs license agreement with France-based Lysogene to boost its gene therapy portfolio.
Top Research Reports for Pfizer, Caterpillar & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Pfizer (PFE), Caterpillar (CAT) and Charter Communications (CHTR).
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.92, marking a +1.86% move from the previous day.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS